✨ Free AI Report
Evotec SE: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Evotec SE
Company Research

Evotec SE: Business Overview, Financials & Competitive Analysis

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. The company serves as a strategic partner to pharma and biote...

Analyst-debate audio for Evotec SE

AskCyborg analysts argue the bull and bear cases for Evotec SE across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Turnaround-stage drug discovery platform executing asset-light strategy with strong pharma partnerships, but burdened by margin...

Read the full analyst-debate transcript →
Industry Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Evotec SE Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Evotec SE Overview

Pro stress-test →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. The company serves as a strategic partner to pharma and biotech firms, leveraging AI-driven innovation and advanced technologies to accelerate drug development across multiple therapeutic areas. The company works with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders.

Strategic Profile

Pro stress-test →

Evotec operates in two segments, Shared R&D and Just – Evotec Biologics. The company is executing a strategic portfolio shift toward higher-margin biologics manufacturing and away from lower-margin discovery services. Evotec signed a sale and license agreement with Sandoz on November 4, 2025, transferring the Just - Evotec Biologics Toulouse site and granting an indefinite license to Evotec's continuous biologics manufacturing platform, with key financial terms including approximately US$350m cash for the site, plus upfront license fees and success-based milestones totalling more than US$300m over coming years.

Competitive Landscape

Pro stress-test →

Evotec competes in the crowded CRO/CDMO space against Syneos Health, IQVIA, Parexel (Pamlab), Charles River Laboratories, and WuXi AppTec. The company differentiates through AI-driven platforms, proprietary technology (PanOmics, Molecular Patient Databases, iPSC modeling), and integrated small molecule-to-biologics capabilities. However, discovery services face pricing pressure from larger CROs and emerging competitors.

Industry Context

Evotec SE operates in Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO).

Key facts

Founded: 1993 · Headquarters: Hamburg, Germany · Employees: N/A · Revenue: $797M (2024); €535M (9M 2025) · Market cap: $1.29B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Evotec SE.

  • Just - Evotec Biologics accelerated, with revenues €143.4m, +11.3% and strong non-Sandoz/non-DoD growth.
  • Evotec announced receipt of a US$5 million milestone payment after the U.S. FDA accepted an Investigational New Drug (IND) application for a collaboration-developed CELMoD™ drug candidate from its strategic protein degradation partnership with Bristol Myers Squibb, which is expected to enter Phase 1 in 2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Dr. Sarah Fakih appointed as Executive Vice President, Head of Global Communications and Investor Relations
  • January 2026Gates Foundation grant received for AI-optimised affordable biologics advancement through Just - Evotec Biologics
  • +2 moreTrack every material event for Evotec SE as it happens. Explore monitoring →
Get alerted when Evotec SE has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Contract Research Organization ServicesLeading CRO with preclinical, clinical, and manufacturing services→Integrated Drug DevelopmentGlobal clinical research and data analytics platform→Biologics ManufacturingIntegrated CDMO with cell/gene therapy and manufacturing capabilities→Clinical Development ServicesCRO and contract sales organization services→

Compare Evotec SE with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Evotec SE operates in Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Services / Contract Research Organization (CRO) & Contract Development and Manufacturing Organization (CDMO) research →
NEW · MCP server

Ask your AI assistant about Evotec SE

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Evotec SE and its top competitor on Cyborg Score”
“What did Evotec SE do this quarter?”
“Is Evotec SE a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Evotec SE do?+
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. The company serves as a strategic partner to pharma and biote...
What is Evotec SE's Cyborg Score?+
Evotec SE has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Evotec SE's main competitors?+
Named competitors include Contract Research Organization Services, Integrated Drug Development, Biologics Manufacturing, Clinical Development Services. The full competitive landscape is in the AskCyborg report.
How can I get the full Evotec SE research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Evotec SE research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Evotec SE over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical Services research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Evotec SE